Survival in idiopathic pulmonary fibrosis - cytotoxic agents compared to corticosteroids

Survival in idiopathic pulmonary fibrosis - cytotoxic agents compared to corticosteroids

Autor Pereira, Carlos Alberto de Castro Autor UNIFESP Google Scholar
Nunes, Tatiana Santos Malheiros Autor UNIFESP Google Scholar
Coletta, Ester Nei Aparecida Martins Autor UNIFESP Google Scholar
Ferreira, Rimarcs Gomes Autor UNIFESP Google Scholar
Rubin, Adalberto Sperb Google Scholar
Ota-Arakaki, Jaquelina Sonoe Autor UNIFESP Google Scholar
Rocha, Nailê Sena da Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Resumo Study objective: To compare the survival of patients with IPF treated retrospectively with corticosteroids atone, to survival of patients treated with immunosuppressive and corticosteroids combined. Design: Non-randomized retrospective cohort study.Setting: Three tertiary centers in Brazil.Patients: Eighty-two IPF patients were included. the diagnosis was confirmed by open lung biopsy in 48. Patients received either corticosteroids alone (group 1) or cytotoxic agents in addition to corticosteroids (group 11).Measurements and results: the primary end-point was mortality. Secondary outcome included longitudinal changes in FVC. Mean age was 66+8 years. FVC was 71 +/- 17% of predicted. There were 48 deaths during the study period (59%), 44 secondary to respiratory causes. From preliminary univariate analysis, for the group as a whole, worse survival was found to be associated with FVC% < 70% of predicted (P = 0.004), evidence of disease progression by follow-up FVC measurements (P = 0.01), and pharmacologic treatment (P = 0.014). Median survival was 25 months for the group 1, and 45 months for the group 11 (Log-Rank = 6.45, P = 0.01). After adjusting for FVC >= 70% and < 70% of predicted, there was evidence to indicate that survival was associated with recommended pharmacologic treatment only in patients with FVC >= 70% (Log Rank = 6.84, P = 0.009).Conclusions: the combination of immunosuppressive agents and prednisone results in better survival when compared to prednisone alone in patients with IPF the benefit seems to occur only in patients with less severe disease, as reflected by FVC >= 70%. (c) 2005 Elsevier B.V. All rights reserved.
Palavra-chave fibrosis
pulmonary
fibrosing alveolitis
cyclophosphamide
prednisone
Idioma Inglês
Data de publicação 2006-02-01
Publicado em Respiratory Medicine. London: W B Saunders Co Ltd, v. 100, n. 2, p. 340-347, 2006.
ISSN 0954-6111 (Sherpa/Romeo, fator de impacto)
Publicador W B Saunders Co Ltd
Extensão 340-347
Fonte http://dx.doi.org/10.1016/j.rmed.2005.05.008
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000235243000020
Endereço permanente http://repositorio.unifesp.br/handle/11600/28705

Exibir registro completo




Arquivo

Nome: WOS000235243000020.pdf
Tamanho: 156.2KB
Formato: PDF
Descrição:
Abrir arquivo

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta